Post-marketing safety of vemurafenib: a real-world pharmacovigilance study of the fda adverse event reporting system

HIGHLIGHTS

• who: Kris Warman from the Department of Pharmacy, Pengzhou People`s Hospital, Pengzhou, ChinaUniversity of Science and Technology, Wuhan, China have published the research work: Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System, in the Journal: (JOURNAL)
• what: The authors retrospectively analyzed the AEs reported from the first quarter of 2016 to the third quarter of 2021 with vemurafenib. In the research , rash (PT: 10037844), arthralgia (PT: 10003239), fatigue (PT: 10016256), nausea (PT: 10028813), diarrhoea (PT: 10012735), alopecia (PT: 10001760), decreased appetite (PT: 10061428) were presented . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.